SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as a government shutdown looms, sparking debate about potential market impact. The community is discussing whether history will repeat itself with markets brushing off the event, or if current high valuations and economic fragility will lead to a downturn. Some traders are anticipating volatility and preparing for potential opportunities.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the U.S. government shutdown looms, sparking debate about its potential market impact. While some anticipate a pullback, others believe a shutdown is already priced in or could even be bullish, leading to volatility. Community members are actively discussing potential trading strategies amidst the uncertainty.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around the crypto, emphasizing its ties to culture, freedom, and digital growth. The conversation highlights Weedcoin as more than just a token, but a movement and a symbol of innovation. Community members are also celebrating its trending status alongside other cryptos like $UPDOG.X.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

$BYTE.X is gaining attention as the 'pup' of xAI, with community members suggesting a connection to Elon Musk and a potential role in future AI developments; some users claim that positive sentiment from the community may be fueling Grok, while others point to its strong community as a reason to invest. Amidst the hype, some caution is being urged to DYOR, as a fake Solana token of the same name circulates.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MLTX is trending as the community discusses a potential rebound after a significant drop, speculating that it was an overreaction to trial data. Chatter revolves around the possibility of a short squeeze and a return to previous price levels, with some mentioning a previous buyout offer. Investors are weighing the company's cash position and pipeline, with many expressing a bullish outlook.

Lithium Americas Corp. engages in the development of the Thacker Pass project. It is focused on advancing Thacker Pass to production it is located in northern Nevada. The company was founded on January 23, 2023 and is headquartered in Vancouver, Canada.

Lithium Americas Corp (NewCo)

Lithium Americas Corp

Lithium Americas ($LAC) is trending following confirmation that the U.S. government will take a stake in the company and its Thacker Pass lithium project. This move is viewed by the community as a major win, solidifying the project's importance for domestic lithium supply. Some traders are drawing parallels to previous government-backed runs in other sectors, anticipating a significant price increase.

its a Meme token and beta to Troll The "Lenny face  is a text-based emoticon, ( ͡° ͜ʖ ͡°), used to convey a range of emotions, particularly mischief, sexual innuendo, or a hidden meaning. It's often employed in online discussions to add a playful or suggestive tone to a message, or sometimes even to spam threads, according to Wikipedia. The symbol is visually interpreted as a face with two eyes (small circles), a nose (squiggly line), and a mouth (curved line).

Lenny

$LENNY.X is trending as the community rallies around the 'Lenny face' meme, calling it the 'OG internet meme' and a 'digital fossil fuel'. Community members are expressing strong conviction, emphasizing community-building, dismissing concerns around dips, and touting the potential for significant gains, referring to themselves as the 'Lenny Army'.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid discussions about a potential government shutdown and its implications, with community members debating the political blame and potential economic consequences. Some investors are expressing concerns about the stock's performance, while others remain supportive of the company and its leadership. Broader political issues, such as military involvement in domestic affairs and healthcare funding, are also being actively discussed in relation to the stock.

Bakkt Holdings, Inc. engages in the intersection of cryptoassets, loyalty and rewards, and payments. It also provides a platform to expand payment offerings, create new revenue streams, and increase customer loyalty. The company was founded in 2018 and is headquartered in Alpharetta, GA.

Bakkt Holdings Inc - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is trending due to renewed interest after a new board appointment, sparking discussions about the company's potential growth strategy within the digital asset space. Bullish sentiment is building around the possibility of a short squeeze and the company's strengthened financial position. The community is actively speculating about the impact of new leadership and potential partnerships.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is seeing community discussion driven by a recent price dip and overall market volatility, with some traders seeing a buying opportunity while others remain cautious. The potential for a near-term bounce and the impact of possible Fed rate cuts are key talking points. Long-term call buying is also being noted, suggesting some believe in a longer-term bullish outlook for the crypto ETF.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure

Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.

Soleno Therapeutics (SLNO) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Soleno Therapeutics (SLNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Shares of Soleno Therapeutics (SLNO) tumbled 14% on Wednesday following the news of the death of a patient treated with the company’s Vykat XR drug.The company stated in a filing with the Securities and Exchange Commission that it is aware of a serious adverse event reported in the U.S. Food and Drug Administration’s (FDA) Adverse Event Reporting System (FAERS) involving a deceased patient. However, the existence of a report in the data does not establish causation, the company said.Soleno said that its assessment of the death is the same as the treating physician, who said that the death is not related to the treatment with Vykat XR. The 17-year-old boy had a history of comorbidities, including lymphedema, superficial thrombophlebitis, and obesity, the company said, while adding that he died from an apparent pulmonary embolus.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001484565/000119312525199882/d88981d8k.htm">said</a> that Vykat XR has a proven safety and efficacy profile and was approved by the FDA following a rigorous clinical program.“Going forward, Soleno does not intend to specifically comment on adverse events cases (including deaths) unless directly related to VYKAT XR use and unexpected per the U.S. Prescribing Information,” the company stated, while adding that the patient population treated with Vykat XR has significant comorbidities and a markedly reduced life expectancy.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SLNO">SLNO stock</a> stayed within ‘bearish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:624/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_10_at_2_04_40_PM_png_3f94f5b623.webp" alt="SLNO's Sentiment Meter and Message Volume as of 2:05 p.m. ET on Sept. 10, 2025 | Source: Stocktwits" width="624" height="62"><figcaption>SLNO's Sentiment Meter and Message Volume as of 2:05 p.m. ET on Sept. 10, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user hinted they are exiting their position.<stembedurl>https://stocktwits.com/Mik21212/message/628184514</stembedurl>Another user, however, highlighted that the death was unrelated to the drug.<stembedurl>https://stocktwits.com/Zzzquil/message/628178500</stembedurl>Soleno <a href="https://stocktwits.com/news-articles/markets/equity/soleno-therapeutics-gets-fda-approval-for-prader-willi-syndrome-drug/chJ25DRRbE3">received</a> the U.S. Food and Drug Administration’s approval for Vykat XR extended-release tablets for the treatment of hyperphagia in patients four years of age and older with Prader-Willi syndrome in March and subsequently launched it in April. Vykat XR is the company’s first commercial product.Prader-Willi syndrome is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15, estimated to occur in one in every 15,000 live births. The disorder is defined by hyperphagia, an intense, persistent sensation of hunger, which could be life-threatening.Last month, Scorpion Capital <a href="https://stocktwits.com/news-articles/markets/equity/soleno-therapeutics-stock-slumps-after-scorpion-capital-reveals-short-position/chsPUzYRdfU">revealed</a> a short position on the stock, alleging several risks associated with Vykat XR, including high risk of pre-diabetes/diabetes, pulmonary edema, and congestive heart failure. Scorpion Capital also stated that it intends to submit an emergency Citizen Petition shortly, requesting that the FDA urge Soleno to conduct a voluntary recall of Vykat XR from the market.SLNO stock is up 34% this year and approximately 22% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-stock-rises-after-company-launches-treatment-plans-for-low-testosterone/chwkjBwRduy">Hims &amp; Hers Stock Rises After Company Launches Treatment Plans For Low Testosterone</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Soleno Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Soleno Therapeutics Stock Tanks After Patient Treated With Drug Dies – More Details Inside

Soleno said that its assessment of the death is the same as the treating physician, who said that the death is not related to the treatment with Vykat XR.

Equity

Soleno said that its assessment of the death is the same as the treating physician, who said that the death is not related to the treatment with Vykat XR.


Down 21.7% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround 

The heavy selling pressure might have exhausted for Soleno Therapeutics (SLNO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Shares of Soleno Therapeutics (SLNO) slumped 7% on Friday afternoon after Scorpion Capital revealed a short position on the stock, citing risks associated with the company’s drug approved for Prader-Willi syndrome.The shortseller alleged several risks associated with Vykat XR, including high risk of pre-diabetes/diabetes, pulmonary edema, and congestive heart failure. It further alleged that the drug may be at risk of being withdrawn from the market, or new prescriptions may plunge.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SLNO">Soleno</a> trended in the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1366/124;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_15_at_12_42_29_PM_png_0f8718e0b7.webp" alt="SLNO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Aug. 15, 2025 | Source: Stocktwits" width="1366" height="124"><figcaption>SLNO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Aug. 15, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user dismissed the short seller report, citing inconsistencies with public data.<stembedurl>https://stocktwits.com/aristocks/message/625341208</stembedurl>Another believes the stock is a good buy-the-dip candidate.<stembedurl>https://stocktwits.com/CrispDry/message/625323181</stembedurl>Scorpion Capital said in its report that Soleno is reminiscent of the company Zafgen, which announced two patient deaths in 2015 during a trial with an investigational Prader-Willi syndrome drug, leading to discontinuation of the program. Zafgen subsequently merged with Larimar Therapeutics in 2020.“SLNO is at high risk of fading back into obscurity as a zombie biotech that trades near cash - $9/share - round-tripping back to single-digit or penny stock status, as it was a mere ~2.5 years ago when it hit 90 cents,” Scorpion Capital <a target="_blank" rel="noopener noreferrer nofollow" href="https://scorpionreports.s3.us-east-2.amazonaws.com/SLNO1.pdf">said</a> in its report. The firm further alleged that Soleno has “no meaningful assets, pipeline or scientific program, and its only drug is an inferior tablet version of a half-century-old suspension.”Scorpion Capital also stated that it intends to shortly submit an emergency Citizen Petition asking the FDA to request Soleno to conduct a voluntary recall of VYKAT XR from the market.Soleno <a href="https://stocktwits.com/news-articles/markets/equity/soleno-therapeutics-gets-fda-approval-for-prader-willi-syndrome-drug/chJ25DRRbE3">received</a> the U.S. Food and Drug Administration’s approval for Vykat XR extended-release tablets for the treatment of hyperphagia in patients four years of age and older with Prader-Willi syndrome in March and subsequently launched it in April. VYKAT XR is the company’s first commercial product.Prader-Willi syndrome is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15, estimated to occur in one in every 15,000 live births. The disorder is defined by hyperphagia, an intense, persistent sensation of hunger, which could be life-threatening.Scorpion Capital has previously revealed short positions in multiple pharmaceutical and biotechnology companies, including Transmedics Group Inc (TMDX), Harmony Biosciences (HRMY), Twist Bioscience (TWST), and more.SLNO stock is up by 60% this year and by about 42% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/cleveland-cliffs-enters-multi-year-steel-deals-with-automakers-report/chsPDjERdfH">Cleveland-Cliffs Enters Multi-Year Steel Deals With Automakers, Says Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Soleno Therapeutics Stock Slumps After Scorpion Capital Reveals Short Position: But Retail’s Not Pessimistic Yet

The shortseller alleged several risks associated with Vykat XR, including high risk of pre-diabetes/diabetes, pulmonary edema, and congestive heart failure.

How Much Upside is Left in Soleno Therapeutics (SLNO)? Wall Street Analysts Think 43.15%

The average of price targets set by Wall Street analysts indicates a potential upside of 43.2% in Soleno Therapeutics (SLNO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Here's Why Momentum in Soleno Therapeutics (SLNO) Should Keep going

Soleno Therapeutics (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates

Soleno Therapeutics (SLNO) delivered earnings and revenue surprises of +83.02% and +1.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Soleno Therapeutics, Inc. (SLNO) is a Great Momentum Stock: Should You Buy?

Does Soleno Therapeutics, Inc. (SLNO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Can Soleno Therapeutics (SLNO) Climb 33.11% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Soleno Therapeutics (SLNO) points to a 33.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Current Price	$67.60
Prev Close	$68.16
Open	$68.46
Dividend Yield	0.00%
50-Day Moving Average	$71.48
Beta	0.80
Avg. Volume	1.6M
PE Ratio	-16.44

52-Week High	$90.32
52-Week Low	$41.50
Market Capitalization	$3.62B
EPS (Annual)	-$4.38
Price to Book	14.32
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

SLNO
Soleno Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLNO News

SLNO Soleno Therapeutics Inc